Virus-specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection
Overview
Affiliations
Unlabelled: Severe acute respiratory syndrome coronavirus (SARS-CoV) caused an acute human respiratory illness with high morbidity and mortality in 2002-2003. Several studies have demonstrated the role of neutralizing antibodies induced by the spike (S) glycoprotein in protecting susceptible hosts from lethal infection. However, the anti-SARS-CoV antibody response is short-lived in patients who have recovered from SARS, making it critical to develop additional vaccine strategies. SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection, a time at which memory B cells and antivirus antibodies were undetectable in individuals who had recovered from SARS. In this study, we assessed the ability of virus-specific memory CD8 T cells to mediate protection against infection in the absence of SARS-CoV-specific memory CD4 T or B cells. We demonstrate that memory CD8 T cells specific for a single immunodominant epitope (S436 or S525) substantially protected 8- to 10-month-old mice from lethal SARS-CoV infection. Intravenous immunization with peptide-loaded dendritic cells (DCs) followed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in accumulation of virus-specific memory CD8 T cells in bronchoalveolar lavage fluid (BAL), lungs, and spleen. Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced multiple effector cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme B) and reduced lung viral loads. Overall, our results show that SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection, but they also suggest that SARS-CoV-specific CD4 T cell and antibody responses are necessary for complete protection.
Importance: Virus-specific CD8 T cells are required for pathogen clearance following primary SARS-CoV infection. However, the role of SARS-CoV-specific memory CD8 T cells in mediating protection after SARS-CoV challenge has not been previously investigated. In this study, using a prime-boost immunization approach, we showed that virus-specific CD8 T cells protect susceptible 8- to 10-month-old mice from lethal SARS-CoV challenge. Thus, future vaccines against emerging coronaviruses should emphasize the generation of a memory CD8 T cell response for optimal protection.
Wang X, Yang X, Zhang X, Yan H, Jin J, Ma Z Front Immunol. 2025; 16:1554409.
PMID: 40070834 PMC: 11893571. DOI: 10.3389/fimmu.2025.1554409.
Worzner K, Schmidt S, Zimmermann J, Tami A, Polacek C, Fernandez-Antunez C EBioMedicine. 2025; 113:105615.
PMID: 39983329 PMC: 11893338. DOI: 10.1016/j.ebiom.2025.105615.
Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V HLA. 2025; 105(1):e70011.
PMID: 39807702 PMC: 11731316. DOI: 10.1111/tan.70011.
Ko K, Bae H, Park J, Lee J, Park S, Heo J Nat Commun. 2024; 15(1):10368.
PMID: 39609429 PMC: 11604757. DOI: 10.1038/s41467-024-54620-4.
Lung Immune Cell Niches and the Discovery of New Cell Subtypes.
Shan Q, Qiu J, Dong Z, Xu X, Zhang S, Ma J Adv Sci (Weinh). 2024; 11(45):e2405490.
PMID: 39401416 PMC: 11615829. DOI: 10.1002/advs.202405490.